Corvus Pharmaceu Stock Price, News & Analysis

Corvus Pharmaceuticals (NASDAQ:CRVS) completed an underwritten public offering of 9,783,660 shares at $3.50 per share, raising gross proceeds of $34.2 million. This includes 1,212,231 shares from underwriters’ partial exercise of their option. The net proceeds for Corvus stand at approximately $31.8 million after expenses. Cantor Fitzgerald & Co. and H.C. Wainwright & Co. are the joint book-running managers for the offering. The shares' offering was made under an effective registration statement with the SEC.

Corvus Pharmaceuticals (NASDAQ:CRVS) has announced the pricing of a public offering of 8,571,429 shares of common stock at $3.50 per share, totaling gross proceeds of $30 million. The offering will support the Phase 3 clinical trial of CPI-006 and the development of other product candidates. Additionally, underwriters have a 30-day option to purchase an extra 1,285,714 shares. The offering is set to close around February 17, 2021, pending customary closing conditions.

Corvus Pharmaceuticals (NASDAQ:CRVS) announced a public offering of its common stock, with all shares being sold by the company. Underwriters may purchase an additional 15% of the shares offered. The company plans to utilize the net proceeds for its Phase 3 clinical trial of CPI-006 and other product developments. The offering is subject to market conditions, and a registration statement for these securities was filed with the SEC.

Corvus Pharmaceuticals (NASDAQ: CRVS) has initiated a Phase 3 clinical trial for CPI-006, targeting hospitalized COVID-19 patients. This randomized, double-blind, placebo-controlled study aims to enroll around 1,000 participants globally, with results expected in Q4 2021. Preliminary Phase 1 results showed promising outcomes, with no patients progressing to mechanical ventilation and a median hospital discharge time of 3.5 days. CPI-006 aims to stimulate B cells for enhanced antibody production, potentially addressing SARS-CoV-2 variants. A separate Phase 2 trial is planned for CPI-818 in T-cell lymphoma.

Corvus Pharmaceuticals (NASDAQ: CRVS) reported new interim data on CPI-818 at the 62nd ASH Annual Meeting, showcasing its potential in treating T cell lymphomas and autoimmune lymphoproliferative syndrome (ALPS). The Phase 1/1b trial revealed promising anti-tumor activity, with significant tumor responses in advanced T cell malignancies. No severe treatment-related adverse events were recorded. Additionally, pre-clinical data indicated that CPI-818 could inhibit abnormal T cell activation in ALPS patients. The company plans to continue its studies and collaborate with Angel Pharmaceuticals in China.

Corvus Pharmaceuticals (CRVS) has announced new findings on its drug CPI-818 at the upcoming 62nd ASH Annual Meeting. The data includes results from a Phase 1/1b trial focused on T cell lymphoma and pre-clinical studies for treating autoimmune lymphoproliferative syndrome (ALPS). CPI-818 is an ITK inhibitor showing potential in blocking T cell activation in ALPS patients. Presentations will occur on December 5 and 6, 2020, highlighting CPI-818's efficacy and safety.

Corvus Pharmaceuticals (CRVS) announced the initiation of a pivotal Phase 2 randomized trial for CPI-006, aimed at treating COVID-19 in hospitalized patients. This trial is expected to start in December 2020, with results anticipated by mid-2021. The Phase 1 study demonstrated that CPI-006 activates a strong anti-SARS-CoV-2 antibody response and enhances patient recovery, with no reported drug-related toxicity. Key presentations highlighting the COVID-19 program will occur at the SITC Annual Meeting on November 13, 2020, showcasing CPI-006's immunotherapy potential.

Corvus Pharmaceuticals (NASDAQ: CRVS) announced the completion of patient enrollment in a Phase 1 study of CPI-006, an immunotherapy for hospitalized COVID-19 patients. Data presented at the SITC Annual Meeting indicates that CPI-006 enhances polyclonal humoral immunity, with patients showing significant antibody responses to SARS-CoV-2. Following promising results, a pivotal, randomized trial is set to begin in December 2020, with results anticipated by mid-2021. The R&D Symposium on November 12 will further detail these findings and updates on cancer programs.

Corvus Pharmaceuticals (NASDAQ: CRVS) will host a webcast R&D Symposium on November 12, 2020, focusing on its COVID-19 program and cancer updates. The event features key presentations, including an oral presentation of CPI-006 data at the SITC Annual Meeting from November 9-14, 2020. CPI-006 showed promise in stimulating immune response in mild to moderate COVID-19 patients. The symposium will discuss ongoing clinical trials and invite questions from attendees, providing insights into Corvus's innovative approaches in immunotherapy.